MATRIX METALLOPROTEINASES AS MARKERS OF RESPIRATORY TRACT REMODELING AND POTENTIAL THERAPEUTIC TARGET IN PATIENTS WITH BRONCHIAL ASTHMA

It is evidently known that chronic inflammatory process in the bronchi of patients with bronchial asthma associated emergence and progression airway remodeling, resulting irreversible obstruction. However, exact mechanisms connection between inflammation remodeling are not very well understood reason for delay development new specific targeted drugs aimed to inhibit remodeling. Therefore, our goal was analyze systematize data on role matrix metalloproteinases occurrence possibility therapeutic effects this process. Materials methods: search information influence processes its pharmacological correction electronic databases such as PubMed Google Scholar over past 25 years. Matrix metalloproteinase-9 tissue proteinase-1 inhibitor have been shown play most important presence asthma, supported by numerous experimental clinical studies. Much attention paid comparison these indicators bronchoalveolar lavage, induced sputum blood background exacerbation a stable course disease. The analysis their content depending severity course, dysfunction external respiration degree reversibility Studies drug markers low efficacy. results contradictory, but them prove metalloproteinase-9, protease inhibitor-1 relationship and, consequently, disease, which dictates need develop additional treatments.